Connect with others who understand.

  • Learn from expert-reviewed resources
  • Real advice from people who’ve been there
  • People who understand what you’re going through
Sign Up Log In
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.
April 14
 · 
Reactions
A MyMyelomaTeam Member

Donna, my immune system has been pretty much destroyed by my various treatments so I get weekly SCIG treatments (Hizentra-4 sessions equals 1 IV session). Other than no IGA and IGM, my IGG is testing as low normal. Avoidance of groups has helped prevent infections. So far it is great.

April 14
A MyMyelomaTeam Member

Serge, I have been on Tecvayli for over a year. My frequency of shots has been reduced from weekly, to biweekly, and finally to monthly. The dose has remained the same. My doctors say I am in remission and I have been feeling better and better. I hope you are doing well also! Best wishes!

April 14
A MyMyelomaTeam Member

Serge and Martin, this is very good news. Are you having any major side effects like frequent infections? Do you require monthly IVIG?

April 14
MyMyelomaTeam

Have others been on or are still getting Tecvayli shots?

It's great to hear you've been doing well on Tecvayli for 2 years! That's a positive sign that the treatment is working for you.

Tecvayli (teclistamab-cqyv) is used for people with relapsed or refractory multiple myeloma who have already tried at least four other Show Full Answer

Have others been on or are still getting Tecvayli shots?

It's great to hear you've been doing well on Tecvayli for 2 years! That's a positive sign that the treatment is working for you.

Tecvayli (teclistamab-cqyv) is used for people with relapsed or refractory multiple myeloma who have already tried at least four other treatments. It was the first FDA-approved BCMA bispecific antibody for myeloma, receiving approval in October 2022.

The medication works by connecting myeloma cells to your T cells, which then helps destroy the cancer cells. It's given as a subcutaneous injection (a shot under the skin).

In clinical trials, Tecvayli showed an overall response rate of 62 percent, meaning many people experienced improvement in their myeloma.

Your experience of doing well for 2 years is encouraging! Many MyMyelomaTeam members share their treatment experiences on the platform, so you're likely not alone in your Tecvayli journey. Continuing to monitor how you're doing with your healthcare team is important for maintaining your positive response.

April 14

Related Questions

View All
A MyMyelomaTeam Member asked a question 💭
Northcreek,ny

A MyMyelomaTeam Member asked a question 💭
Northcreek,ny